Walmart, CVS Caremark reach deal to continue prescription drug coverage

Walmart, CVS Caremark reach deal to continue prescription drug coverage

A number of other large investors have also modified their holdings of the business.

A total of 6 analysts rate CVS Health (NYSE:CVS) as follows: 4 "Buy", 2 "Hold" and 0 "Sell". Hayek Kallen Investment Management raised its holdings in shares of CVS Health by 5.0% during the third quarter. Northcoast Asset Mgmt Limited Liability Company owns 26,822 shares. Moreover, Randolph has 3.66% invested in CVS Health Corporation (NYSE:CVS) for 279,395 shs. Plimoth Trust Co. LLC now owns 32,172 shares of the pharmacy operator's stock valued at $2,533,000 after purchasing an additional 720 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of CVS Health by 15.9% during the 2nd quarter. Vanguard Group Inc now owns 84,873,814 shares of the pharmacy operator's stock valued at $6,681,267,000 after purchasing an additional 1,445,887 shares in the last quarter.

Steven Halper, an analyst at Cantor Fitzgerald, said resolving the dispute would benefit CVS and its customers, even if CVS had to pay Walmart higher prices than it wanted.

At time of publication, Walmart traded up marginally at $97.40, while CVS traded up 2.5 percent at $64.95. They set an "overweight" rating and a $91.00 price target for the company. "Buy" rating has 4, "Sell" are 0, while 2 are "Hold". On average, these analysts now have a Strong Buy recommendation with a mean rating of 4.55. Also, EVP Troyen A. Brennan sold 14,229 shares of the firm's stock in a transaction on Wednesday, November 14th. The shares were sold at an average price of $82.00, for a total transaction of $1,166,778.00.

A frequently relied-upon technique for evaluating any given stock's value at a particular point is by viewing its current price in relation to its 52-week range.

More news: SNL's Trump will end the shutdown for a 'hamberder'

While the disagreement between the two companies reportedly centered on prescription fulfillment fees, the press release did not disclose the agreement's financial terms. The disclosure for this sale can be found here. As recorder after this particular trading period, this stock managed to pump out a noticeably lower trading volume than its normal average of 9.70M per day (as observed over the last 3 months of trading).

CVS stock opened at $65.52 on Friday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.94 and a current ratio of 2.44. Listed here are CVS Health Corporation (NYSE:CVS) PTs and latest ratings. The pharmacy operator reported $1.73 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.71 by $0.02. CVS Health had a return on equity of 18.69% and a net margin of 1.65%. The company had revenue of $47.27 billion during the quarter, compared to analysts' expectations of $47.22 billion. That's up 11.46 % from last year's $1.92 EPS. That is 11.46 % up compareed to $1.92 EPS for past year. Stockholders of record on Friday, January 25th will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Thursday, January 24th.

Mercer Advisers Inc reported 0.08% of its portfolio in CVS Health Corporation (NYSE:CVS). If you are viewing this report on another site, it was stolen and reposted in violation of United States and worldwide trademark and copyright law. UBS Group began coverage on CVS Health in a research note on Thursday.

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services.The firm is valued at $81.95 billion. It operates through Pharmacy Services and Retail/LTC divisions.20.84 is the P/E ratio. Its prescription plans for those on the government-run Medicare program were unaffected by the contract dispute as was its Sam's Club agreements.